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Research in genetics and immunology was going on separate strands for a long time. Type 1 diabetes mellitus might not be
characterized with a single pathogenetic factor. It develops when a susceptible individual is exposed to potential triggers in a
given sequence and timeframe that eventually disarranges the fine-tuned immune mechanisms that keep autoimmunity under
control in health. Genomewide association studies have helped to understand the congenital susceptibility, and hand-in-hand
with the immunological research novel paths of immune dysregulation were described in central tolerance, apoptotic pathways, or
peripheral tolerance mediated by regulatory T-cells. Epigenetic factors are contributing to the immune dysregulation.The interplay
between genetic susceptibility and potential triggers is likely to play a role at a very early age and gradually results in the loss of
balanced autotolerance and subsequently in the development of the clinical disease. Genetic susceptibility, the impaired elimination
of apoptotic 𝛽-cell remnants, altered immune regulatory functions, and environmental factors such as viral infections determine
the outcome. Autoreactivity might exist under physiologic conditions and when the integrity of the complex regulatory process is
damaged the disease might develop. We summarized the immune regulatory mechanisms that might have a crucial role in disease
pathology and development.
1. Introduction
Type 1 diabetes (T1DM) is known to be the result of the
selective damage of pancreatic 𝛽-cells. Other cell types of
the Langerhans islets are preserved. However, the lack of
insulin causes a secondary disinhibition of the glucagon-
secreting 𝛼-cells [1]. The destruction of the 𝛽-cells is the
consequence of a cell-mediated immune response mediated
by islet-infiltrating lymphocytes andmacrophages (insulitis).
Cytokines secreted by macrophages are toxic for 𝛽-cells
[2]; CD8+ cytotoxic lymphocytes are able to damage them
by pore formation [3]. Autoantibodies that give the basis
of clinical diagnosis are known to be secondary factors.
However, promising experimental data has been published
based on autoantibody neutralisation in nonobese diabetic
(NOD) mice, one of the best known models of the human
disease [4]. The knowledge about genetic predisposition has
increased significantly in the last few decades. We know
more genetic variants besides the HLA (human leukocyte
antigen) alleles which are responsible for the most significant
susceptibility. Although the role of genetic factors in the
development of the disease is well established, by itself it
seems to be insufficient to explain all the pathophysiological
features of the disease. The role of numerous environmental
factors is justified by experimental and epidemiological data.
Nevertheless, none has been proven to be a main or generally
accepted cause of the disease. More and more publications
are raising the question whether autoimmunity under all
circumstances would possess a definitely pathologic nature
[5]. In this paper, we summarized the immunoregulatory
processes including those recently put into the focus of T1DM
development.
2. Immune Tolerance and Genetic Factors
According to twin studies, the cumulative significance of
genetic features is estimated to be as high as 50 to 65% [6, 7].
Approximately 70% of type 1 diabetic carry a HLA risk allele
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as the strongest genetic factor. However, only 3–7% of those
carrying such a HLA haplotype will ever become a patient
with manifest type 1 diabetes [8]. Although NOD mice are
the most commonly used models of the human disease and
have high susceptibility, not all develop diabetes. However,
insulitis occurs in each animal [9]. Two questions might be
raised: what is necessary for the development of the insulitis?
and what is necessary for its progression to diabetes? The
discovery of genetic features and immunological events went
on separate threads for a long time. The correlation between
susceptibility and some major histocompatibility complex II
(MHC-II) alleles (DR3-DQ2, DR4-DQ8) has been known
to be linked to the highest (with an odds ratio—OR—of
nearly seven) increase in risk [10]. Recently, some MHC-I
loci were also identified among the genetic risk factors [11].
Besides the obvious role of the MHC class II and I in antigen
presentation, there is an increasing number of non-HLA
alleles associated with the development of type 1 diabetes.
More than seventy non-HLA genes have been reported to
date in the GWAStudies (genomewide association study)
Catalogue based on ten large GWAScans that have variants
contributing to the genetic susceptibility for T1DMwith odds
ratios typically below 2 (also see Table 1) [10, 12–20].
The first selection to filter autoreactive B- and T-lympho-
cyte clones occurs in the primary immune organs (bone
marrow and thymus, resp.) where clones strongly bound to
own (auto)antigens are eliminated. During the formation
of the central tolerance, the autoreactive clones can be
deleted or their receptor might be corrected through editing
[21, 22]. Autoreactive T-cells which reach the periphery
may become anergic due to being continuously flooded
with self-antigens without costimulatory signals. The selec-
tion of T- and B-lymphocytes offers a mutual protec-
tion against autoimmune tendencies of each other. This
is partly because B-lymphocytes are professional antigen-
presenting cells (APCs), and partly because an autoreactive
B-lymphocyte needs Th2 (helper T-cell, subset 2) help to
expand. However, it is still possible that in some infections
the pathogen-specific T-cells might be able to provide Th2
help for the autoreactive B-lymphocytes through bystander
activation (as discussed later) [23]. Furthermore, in patholog-
ical conditions previously hidden self-antigens may become
recognizable, leading to antigen spreading [24]. While the
central tolerance is overwhelmingly genetically determined,
peripheral tolerance is multifactorial.
In the selection of autoreactive T-cell clones, the antigen
presentation in central lymphoid organs is crucial. Genetic
background influencing the presentation of insulin in the
thymus is able to weaken central immune tolerance. Those
having shorter variable number tandem repeat sequences in
the IDDM2 (insulin-dependent diabetes mellitus 2) locus
located upstream from the insulin gene are more susceptible
to autoimmune diabetes [10, 25]. In the presence of longer
VNTRs, higher levels of insulin mRNA expression could
be detected in the thymus. This is likely to contribute to
antigen presentation with higher efficacy eventually leading
to better immune tolerance [25]. When insulin expression
was abrogated in the thymus using a knockout of Ins2 gene
specifically in the AIRE (autoimmune regulator) expressing
medullary thymic epithelial cells of mice, without affecting
its expression in the beta-cells, diabetes developed in three
weeks of age independent of sex [26].
In the central lymphoid organs, not all human antigens
are present. Furthermore, after the central selection, the
escape of autoreactive clones is minimal but not excluded
in healthy individuals. The generation of autoreactive B-
lymphocyte clones is possible even in the germinal centers
through somatic hypermutation [23]. As the immune system
contacts a large number of antigens during life, the optimal
balance should be set in the periphery. In this process, the
role of Treg cells is critical. However, they do not form a
homogenous population. Autoreactivity is not a binary prop-
erty, even in the thymus the affinity of a T-cell to a peptide
might vary on a wide range. Some of the T-cells that bind self-
antigens become natural Treg cells (nTreg) and support active
immune tolerance [27]. At the same time, induced Treg cells
(iTreg) develop in the periphery from naive CD4+ T-cells.
These iTreg cells may have a function either in maintaining
immune tolerance under tolerogenic circumstances (such as
the antigens sensed in the gutmucosa under physiologic con-
ditions) and in limiting the process in inflammation. Besides
the T-cell receptor (TCR), signal transforming growth fac-
tor 𝛽 (TGF-𝛽) and interleukin 2 (IL-2) seem to be minimal
requirements for iTreg cell induction and also the role of
APCs seems to be crucial in iTreg development [28]. In this
perspective, we should mention that T1DM-associated SNPs
(single-nucleotide polymorphisms) were reported directly
in the IL-2 [29, 30]—IL2-RA (IL-2 receptor 𝛼-chain, also
known as CD25) [12–14] axis (see Table 1). Expression of
high levels of CD25 had been the most important marker
of Treg cells before Foxp3 (forkhead box P3) became known.
The antigen presentation will be tolerogenic and favorable
for Treg induction provided that the MHC-II expression
on the APC is low and also the amount of costimulatory
signals from APC remains limited. This can happen when
there are no induction signals (as described later) for the
maturation of dendritic cells (DCs). Furthermore, certain
DCs are able to produce retinoic acid which is able to abrupt
the effect of cytokines (such as IL-4, IFN-𝛾) that would
otherwise suppress the Treg inductive effect of TGF-B and IL-
2, and retinoic acid eventually enhances iTreg development
[28, 31, 32]. Macrophages in the intestinal mucosa exhibited
lower Toll-like receptor (TLR) sensitivity compared to splenic
macrophages, and by IL-10 and retinoic acid production they
contribute to Treg induction and oral tolerance [33]. The
Treg cells inhibit inflammation and contribute to further Treg
induction via their own IL-10 and TGF-𝛽 secretion. Besides
humoral stimuli, low cell surface CD28 and high cytotoxic
T lymphocyte antigen 4 (CTLA-4) signaling promote iTreg
induction [34]. The binding of the T-cell surface CD28
to the B7 complex of the APC is the best known and
most important costimulus in T-cell activation. CTLA-4
also binds to the B7 complex and this way abrogates this
signaling. Its expression in high levels is typical of Treg cells
[23]. Lu¨hder et al. could achieve prompt manifestation of
T1DM in BDC2.5 TCR transgenic mice backcrossed onto
the NOD genetic background by CTLA-4 inhibition which
Clinical and Developmental Immunology 3
Ta
bl
e1
:T
1D
M
-a
ss
oc
ia
te
d
no
n-
M
H
C
ris
kp
ol
ym
or
ph
ism
s(
SN
Ps
)w
ith
an
od
ds
ra
tio
ab
ov
e1
.4
an
d
th
er
ep
or
te
d/
m
ap
pe
d
ca
nd
id
at
eg
en
es
in
G
W
A
St
ud
ie
sr
an
ke
d
by
th
eh
ig
he
st
co
rr
es
po
nd
in
g
od
ds
ra
tio
(O
R)
va
lu
es
in
ad
di
tio
n
to
th
ec
an
di
da
te
ge
ne
s(
CT
LA
4,
IF
IH
1,
IL
2,
an
d
PT
PN
2)
th
at
du
et
o
th
ei
ri
m
m
un
ol
og
ic
al
fu
nc
tio
ns
ha
ve
be
en
di
sc
us
se
d
in
de
ta
il
in
th
et
ex
t.
Re
gi
on
SN
Ps
Re
po
rt
ed
ge
ne
(s
)
M
ap
pe
d
ge
ne
O
dd
s
ra
tio
Ri
sk
al
le
le
fre
qu
en
cy
𝑃
va
lu
e
G
en
ep
ro
du
ct
fu
nc
tio
n
[4
2]
C
on
te
xt
In
iti
al
sa
m
pl
e
siz
e
Re
pl
ic
at
io
n
sa
m
pl
e
siz
e
Pl
at
fo
rm
(S
N
Ps
pa
ss
in
g
Q
C)
Re
fe
re
nc
es
1p
13
.2
rs
66
79
67
7
PH
TF
1,
PT
PN
22
PH
TF
1-
RS
BN
1
1,8
9
0,
1
1𝐸
−
40
PH
TF
1:
tr
an
sc
rip
tio
n
fa
ct
or
;R
SB
N
1:
no
tf
ul
ly
ch
ar
ac
te
riz
ed
In
te
rg
en
ic
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
29
97
tr
io
s,
4,
00
0
ca
se
s,
5,
00
0
cn
tr
l
Se
e[
15
]
[1
0]
rs
24
76
60
1
PT
PN
22
PT
PN
22
N
R
N
R
9𝐸
−
85
Ly
m
ph
oi
d-
sp
ec
ifi
c
in
tr
ac
el
lu
la
rp
ho
sp
ha
ta
se
,a
ne
ga
tiv
er
eg
ul
at
or
of
m
an
y
sig
na
lt
ra
ns
du
ct
io
n
pa
th
w
ay
s
M
iss
en
se
7,5
14
ca
se
s,
9,0
45
cn
tr
l
4,
26
7
ca
se
s,
4,
67
0
cn
tr
l,
4,
34
2
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[1
3]
1,8
0,
09
1𝐸
−
07
M
iss
en
se
46
7
tr
io
s,
56
1
ca
se
s,
1,1
43
cn
tr
l
2,
35
0
in
di
vi
du
al
s
in
54
9
fa
m
ili
es
;3
90
tr
io
s
Ill
um
in
a(
54
3,
07
1)
[1
6]
1,9
8
0,
09
2𝐸
−
80
M
iss
en
se
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
29
97
tr
io
s,
4,
00
0
ca
se
s,
5,
00
0
cn
tr
l
Se
e[
15
]
[1
0]
rs
66
79
67
7
PH
TF
1-
RS
BN
1
N
R
N
R
1𝐸
−
40
In
te
rg
en
ic
3,
56
1c
as
es
,
4,
64
6
cn
tr
l
6,
22
5
ca
se
s,
6,
94
6
cn
tr
l,
3,
06
4
tr
io
s
A
ffy
m
et
rix
(u
p
to
33
5,
56
5)
[14
]
1,8
2
0,
1
5𝐸
−
26
In
te
rg
en
ic
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
Se
e[
10
]
A
ffy
m
et
rix
(4
69
,5
57
)
[1
5]
11
p1
5.
5
rs
10
04
44
6
IN
S
IG
F2
;
IG
F2
-A
S;
IN
S-
IG
F2
1,6
1
0,
65
4𝐸
−
09
In
su
lin
ho
rm
on
e,
IG
F-
2
gr
ow
th
fa
ct
or
In
tro
n
46
7
tr
io
s,
56
1
ca
se
s,
1,1
43
cn
tr
l
2,
35
0
in
di
vi
du
al
s
in
54
9
fa
m
ili
es
;3
90
tr
io
s
Ill
um
in
a(
54
3,
07
1)
[1
6]
rs
37
41
20
8
IG
F2
;
IG
F2
-A
S;
IN
S-
IG
F2
1,2
5
0,
38
2𝐸
−
07
In
tro
n;
nc
RN
A
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
29
97
tr
io
s,
4,
00
0
ca
se
s,
5,
00
0
cn
tr
l
Se
e[
15
]
[1
0]
rs
71
11
34
1
M
IR
46
86
-
A
SC
L2
N
R
N
R
4𝐸
−
48
M
IR
46
86
:m
ic
ro
-R
N
A
;
A
SC
L2
:a
he
lix
-lo
op
-h
el
ix
tr
an
sc
rip
tio
n
fa
ct
or
in
vo
lv
ed
in
th
e
de
te
rm
in
at
io
n
of
th
e
ne
ur
on
al
pr
ec
ur
so
rs
in
th
e
ce
nt
ra
la
nd
pe
rip
he
ra
l
ne
rv
ou
ss
ys
te
m
In
te
rg
en
ic
7,5
14
ca
se
s,
9,0
45
cn
tr
l
4,
26
7
ca
se
s,
4,
67
0
cn
tr
l,
4,
34
2
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[1
3]
10
p1
5.
1
rs
61
83
96
60
IL
2R
A
IL
2R
A
1,6
N
R
5𝐸
−
09
IL
2R
A
:a
sh
om
od
im
er
,a
lo
w
-a
ffi
ni
ty
re
ce
pt
or
of
IL
-2
;R
PL
32
P2
3:
ps
eu
do
ge
ne
;R
BM
17
:a
n
RN
A-
bi
nd
in
g
pr
ot
ei
n,
pa
rt
of
th
es
pl
ic
eo
so
m
ec
om
pl
ex
In
tro
n
16
,17
9
Eu
in
di
vi
du
al
s
N
R
N
R
(6
,2
33
,11
2)
(im
pu
te
d)
[1
2]
rs
12
25
13
07
RP
L3
2P
23
-
RB
M
17
N
R
N
R
1𝐸
−
13
In
te
rg
en
ic
7,5
14
ca
se
s,
9,0
45
cn
tr
l
4,
26
7
ca
se
s,
4,
67
0
cn
tr
l,
4,
34
2
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[1
3]
N
R
N
R
2𝐸
−
06
In
te
rg
en
ic
3,
56
1c
as
es
,
4,
64
6
cn
tr
l
6,
22
5
ca
se
s,6
,9
46
cn
tr
l,
3,
06
4
tr
io
s
A
ffy
m
et
rix
(u
p
to
33
5,
56
5)
[14
]
12
p1
3.
31
rs
37
64
02
1
N
R
CL
EC
2D
1,5
7
0,
47
5𝐸
−
08
C-
ty
pe
le
ct
in
,a
m
em
be
ro
f
th
en
at
ur
al
ki
lle
rc
el
l
re
ce
pt
or
fa
m
ily
,i
nh
ib
its
os
te
oc
la
st
fo
rm
at
io
n
C
ds
-s
yn
on
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
Se
e[
10
]
A
ffy
m
et
rix
(4
69
,5
57
)
[1
5]
4 Clinical and Developmental Immunology
Ta
bl
e
1:
C
on
tin
ue
d.
Re
gi
on
SN
Ps
Re
po
rt
ed
ge
ne
(s
)
M
ap
pe
d
ge
ne
O
dd
s
ra
tio
Ri
sk
al
le
le
fre
qu
en
cy
𝑃
va
lu
e
G
en
ep
ro
du
ct
fu
nc
tio
n
[4
2]
C
on
te
xt
In
iti
al
sa
m
pl
e
siz
e
Re
pl
ic
at
io
n
sa
m
pl
e
siz
e
Pl
at
fo
rm
(S
N
Ps
pa
ss
in
g
Q
C)
Re
fe
re
nc
es
16
p1
3.
13
rs
29
03
69
2
KI
A
A
03
50
CL
EC
16
A
1,5
4
0,
62
7𝐸
−
11
M
em
be
ro
ft
he
C-
ty
pe
le
ct
in
do
m
ai
n
co
nt
ai
ni
ng
fa
m
ily
In
tro
n
46
7
tr
io
s,
56
1
ca
se
s,
1,1
43
cn
tr
l
2,
35
0
in
di
vi
du
al
s
in
54
9
fa
m
ili
es
;3
90
tr
io
s
Ill
um
in
a(
54
3,
07
1)
[1
6]
rs
12
70
87
16
1,1
9
0,
65
5𝐸
−
07
In
tro
n
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
Se
e[
10
]
A
ffy
m
et
rix
(4
69
,5
57
)
[1
5]
1,2
3
0,
68
3𝐸
−
18
In
tro
n
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
29
97
tr
io
s,
4,
00
0
ca
se
s,
5,
00
0
cn
tr
l
Se
e[
15
]
[1
0]
12
p1
3.
31
rs
11
05
25
52
N
R
N
PM
1P
7-
CL
EC
L1
1,4
9
0,
49
7𝐸
−
07
N
PM
1P
7:
ps
eu
do
ge
ne
CL
EC
L1
:t
ra
ns
m
em
br
an
e,
C-
ty
pe
le
ct
in
-li
ke
pr
ot
ei
n
hi
gh
ly
ex
pr
es
se
d
on
de
nd
rit
ic
an
d
B
ce
lls
,m
ay
ac
ta
sa
T-
ce
ll
co
st
im
ul
at
or
y
m
ol
ec
ul
e
In
te
rg
en
ic
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
Se
e[
10
]
A
ffy
m
et
rix
(4
69
,5
57
)
[1
5]
12
q2
4.
12
rs
12
65
56
4
CU
X2
CU
X2
1,4
5
N
R
1𝐸
−
16
A
pr
ot
ei
n
th
at
co
nt
ai
ns
th
re
eC
U
T
do
m
ai
ns
an
d
a
ho
m
eo
do
m
ai
n;
bo
th
do
m
ai
ns
ar
eD
N
A-
bi
nd
in
g
m
ot
ifs
In
tro
n
16
,17
9
eu
in
di
vi
du
al
s
N
R
N
R
(6
,2
33
,11
2)
(im
pu
te
d)
[1
2]
13
q2
2.
2
rs
53
95
14
LM
O
7
LM
O
7
1,4
3
0,
5
6𝐸
−
11
M
ay
be
in
vo
lv
ed
in
pr
ot
ei
n-
pr
ot
ei
n
in
te
ra
ct
io
ns
In
tro
n
9,9
34
eu
ca
se
s,
16
,9
56
eu
cn
tr
l
1,1
20
eu
aff
ec
te
d
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
∼
2.
54
m
ill
io
n)
(im
pu
te
d)
[1
7]
2q
33
.2
rs
30
87
24
3
CT
LA
4
CT
LA
4
N
R
N
R
1𝐸
−
15
Tr
an
sm
its
an
in
hi
bi
to
ry
sig
na
lt
o
T-
ce
lls
N
ea
rG
en
e-
3
7,5
14
ca
se
s,
9,0
45
cn
tr
l
4,
26
7
ca
se
s,
4,
67
0
cn
tr
l,
4,
34
2
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[1
3]
N
R
N
R
8𝐸
−
11
N
ea
rG
en
e-
3
3,
56
1c
as
es
,
4,
64
6
cn
tr
l
6,
22
5
ca
se
s,
6,
94
6
cn
tr
l,
3,
06
4
tr
io
s
A
ffy
m
et
rix
(u
p
to
33
5,
56
5)
[14
]
2q
24
.2
rs
19
90
76
0
IF
IH
1
IF
IH
1
N
R
N
R
7𝐸
−
11
Ac
ts
as
ac
yt
op
la
sm
ic
se
ns
or
of
vi
ra
ln
uc
le
ic
ac
id
s
M
iss
en
se
7,5
14
ca
se
s,
9,0
45
co
nt
ro
ls
4,
26
7
ca
se
s,
4,
67
0
co
nt
ro
ls,
4,
34
2
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[1
3]
1,1
8
0,
6
2𝐸
−
11
M
iss
en
se
1,9
63
ca
se
s,
2,
93
8
co
nt
ro
ls
29
97
tr
io
s,
4,
00
0
ca
se
s,
5,
00
0
co
nt
ro
ls
Se
e[
15
]
[1
0]
4q
27
rs
45
05
84
8
IL
2
KI
A
A
110
9
N
R
N
R
5𝐸
−
13
KI
A
A
110
9:
th
ou
gh
tt
o
fu
nc
tio
n
in
th
er
eg
ul
at
io
n
of
ep
ith
eli
al
gr
ow
th
an
d
di
ffe
re
nt
ia
tio
n
an
d
in
tu
m
or
de
ve
lo
pm
en
t
In
tro
n
7,5
14
ca
se
s,
9,0
45
cn
tr
l
4,
26
7
ca
se
s,
4,
67
0
cn
tr
l,
4,
34
2
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[1
3]
rs
20
69
76
2
IL
2
IL
2
0,
88
9
N
R
N
R
Cy
to
ki
ne
,k
ey
ac
tiv
at
or
of
T-
ce
lls
In
tro
n
85
06
T1
D
M
sa
m
pl
es
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[2
9]
Clinical and Developmental Immunology 5
Ta
bl
e
1:
C
on
tin
ue
d.
Re
gi
on
SN
Ps
Re
po
rt
ed
ge
ne
(s
)
M
ap
pe
d
ge
ne
O
dd
s
ra
tio
Ri
sk
al
le
le
fre
qu
en
cy
𝑃
va
lu
e
G
en
ep
ro
du
ct
fu
nc
tio
n
[4
2]
C
on
te
xt
In
iti
al
sa
m
pl
e
siz
e
Re
pl
ic
at
io
n
sa
m
pl
e
siz
e
Pl
at
fo
rm
(S
N
Ps
pa
ss
in
g
Q
C)
Re
fe
re
nc
es
18
p1
1.2
1
rs
18
93
21
7
PT
PN
2
PT
PN
2
N
R
N
R
4𝐸
−
15
M
em
be
ro
ft
he
pr
ot
ei
n
ty
ro
sin
ep
ho
sp
ha
ta
se
(P
TP
)
fa
m
ily
.R
ep
or
te
d
to
ha
ve
in
hi
bi
to
ry
ro
le
in
be
ta
-c
el
l
ap
op
to
sis
In
tro
n
7,5
14
ca
se
s,
9,0
45
cn
tr
l
4,
26
7
ca
se
s,
4,
67
0
cn
tr
l,
4,
34
2
tr
io
s
A
ffy
m
et
rix
an
d
ill
um
in
a(
84
1,6
22
)
(im
pu
te
d)
[1
3]
rs
25
42
15
1
PS
M
G
2-
PT
PN
2
N
R
N
R
9𝐸
−
08
PS
M
G
2:
pr
ot
ea
so
m
e
as
se
m
bl
y
ch
ap
er
on
e
In
te
rg
en
ic
3,
56
1c
as
es
,
4,
64
6
cn
tr
l
6,
22
5
ca
se
s,
6,
94
6
cn
tr
l,
3,
06
4
tr
io
s
A
ffy
m
et
rix
(u
p
to
33
5,
56
5)
[14
]
1,3
0,
16
1𝐸
−
14
In
te
rg
en
ic
1,9
63
ca
se
s,
2,
93
8
cn
tr
l
29
97
tr
io
s,
4,
00
0
ca
se
s,
5,
00
0
cn
tr
l
Se
e[
15
]
[1
0]
6 Clinical and Developmental Immunology
was not the result of a global T-cell activation but was
caused by a more aggressive T-cell infiltration of the islets
[35]. CTLA-4-deficient mice die at 2-3 weeks of age due to
uncontrolled lymphoproliferation [36]. Risk polymorphisms
of the CTLA-4 gene are linked to T1DM in GWAStudies [10].
CTLA-4 expression was found to be significantly lower on
the mRNA level in T-lymphocytes of children with newly
diagnosed T1DM [37]. Transgenic expression of an agonistic,
membrane-bound single-chain anti-CTLA-4 on pancreatic
𝛽-cells in NODmice could inhibit the autoimmune processes
by selectively targeting CTLA-4 on pathogenic T-cells [38,
39]. The T-cell CTLA-4 expression of NOD mice was found
to be diminished when examined in relation to in vitro anti-
CD3 stimulation. However, the addition of exogenous IL-2
could restore the CTLA-4 expression of NOD CD8 cells to
the level of healthy controls [40]. There is a clinical study in
progress using low-dose IL-2 for therapeutic Treg induction
in T1DM [41]. The study has been completed, but not yet
published.
3. The Janus-Character of Autoimmunity?
Although the role of B-lymphocytes is known to be sec-
ondary in T1DM, which can even develop in cases of severe
congenital B-lymphocyte immunodeficiency [43], Xiu et al.
could significantly delay disease onset with B-lymphocyte
depletion by anti-CD20 antibody in NOD mice. They indi-
cated that this was neither the result of T-cell reduction nor
of Treg induction but it was likely to be the consequence
of the reduced induction of autoreactive T-cells [44]. The
B-lymphocyte activating factor (BAFF, also known as tumor
necrosis factor superfamily member 13b—TNFSF13B—or
B-lymphocyte stimulator—BLyS) secreted by lymphoid stro-
mal cells is necessary for B-lymphocyte survival and in
cases of normal peripheric lymphocyte count autoreactive
B-lymphocytes escaping central deletion might lose in the
competition for BAFF. B-lymphocyte depletion using an anti-
BAFF therapy in prediabetic NOD mice resulted in that the
NOD mice remained diabetes free for at least 50 weeks [45].
On the other hand, transgenic overexpression of BAFF in
mice resulted in the survival of autoreactive B-lymphocytes
in the periphery [46]. Nevertheless, B-lymphocyte depletion
might be a controversial therapy as it might delay the onset
of diabetes in NOD mice, but theoretically it might also be
able to enhance autoimmunity. Although B-lymphocytes as
professional APCs are able to launch immune response, in
vitro results suggest that they might play a regulatory role as
well. In dextran sulfate sodium-induced experimental model
of ulcerative colitis, Yanaba et al. described the presence of
a unique B-lymphocyte population characterized by CD1d
and CD5 marker positivity, which plays a regulatory role
via IL-10 secretion [47]. In the coculture of primary B- and
allogenic T-lymphocytes (B-lymphocytes as APCs) without
additional cytokines, the expansion of Treg cells characterized
by Foxp3 expression was described. The partial inhibition of
the MHC-II-TCR interaction enhanced this process, while
CD28 stimulation by antibodies led to the generation of
effector T-cells [48].
A theory first postulated by Jerne in 1974 might also be
of notable significance. He indicated that the variable regions
of immunoglobulins (idiotypes) may serve as antigens, and
anti-idiotypic immunoglobulins can be produced against
them [49]. Such a system might have a significant role in
determining the intensity of immunological responses and
mediating tolerance. As B-lymphocyte receptors are analo-
gous to the immunoglobulins secreted by the cells and the
B-lymphocytes present the bound antigens throughMHC-II,
blockade of B-lymphocyte receptors is supposed to have a
profound influence on T-cell responses [50]. Furthermore,
variable regions of immunoglobulins share common patterns
with TCRs [51], and effective humoral immune response will
not develop when there is lack of Th2 cells. Wang et al. were
able to delay or, in some cases, even inhibit the onset of T1DM
in NODmice by anti-idiotypic antibodies [4]. A dysfunction
of the anti-idiotypic system in autoimmunity was recently
summarized by Hampe, who also cited that autoantibodies
against glutamate acid decarboxylase in healthy individuals
could be detected, but anti-idiotypic antibodies prevented
them from binding to their target antigen [50].
It is described in rodents [52, 53] and also humans [54]
that a shub of 𝛽-cell death occurs in the perinatal period.
Trudeau et al. mention that in NOD mice insulitis appears
approximately during the fifth week of life and never before
the 15th day, subsequently following the peak of the apoptotic
death wave of 𝛽-cells on the 13th day [53]. Theoretically, this
timeframemight exist due to the immaturity of immune cells,
although Ho¨glund et al.’s finding suggests that T-cells and
APCs in (their) mice are functional on the 10th day of life
[55]. Trudeau et al. compared the apoptotic rate of 𝛽-cells
in diabetes prone and resistant mice and rat strains and
reported no significant difference. However, in NOD mice a
higher amount of apoptotic 𝛽-cell remnants could be shown
using the TUNEL (terminal deoxynucleotidyl transferase
dUTP nick end labeling) method [53]. The dysfunction of
phagocytes (predominantly macrophages) as the first islet
infiltrating cells and their diminished capacity to clean
apoptotic remnants might contribute to this phenomenon
[56, 57]. Although apoptotic cell remnants are generally
thought to have a weak potential to induce immune response,
due to the impaired disposal they can become victims of
secondary necrosis and encounter a stronger immunogenic
potential. APCs have a crucial role in determining the nature
of the antigen presentation.The inhibition of themacrophage
function turned out to be protective against diabetes in NOD
mice—both by the inhibition of antigen presentation and also
by the diminished induction of Th1 type response (due to
weaker IL-12 stimuli) [58]. In contrast, either the enhance-
ment or the inhibition of the apoptotic rate of 𝛽-cells does
not influence the initiation of the disease significantly [59].
On the analogy that in SLE, macrophages have an impaired
apoptotic cell clearance [60], it could be hypothesized that
such macrophage dysfunction may be relevant in T1DM also.
As early as the 80s, it had been demonstrated that human
macrophages had decreased phagocytic capacity in patients
with T1DM [61]. Recently—in addition to the alternative
activation ofmacrophages in T1DM[62]—hypopresponsivity
of macrophages to IFN-𝛾 has been demonstrated in the NOD
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mouse animal model [63], and it is possible that apoptotic
cell clearance itself inhibited the macrophage responses to
a major macrophage activator providing priming signal
IFN-𝛾 [64] and its downstream signaling (JAK-STAT1—Janus
kinase and signal transducer and activator of transcription
1-path).
Turley et al. found that of the NOD and B6.H2g7 mice
strains that carry the same MHC-I and MHC-II haplotype
only theNODmice develop diabetes, although in both strains
potentially diabetogenic T-cells are primed [65]. Danke et al.
described the presence of autoreactive T-cells in healthy indi-
viduals, but in vitro their expansion was inhibited by adding
CD4+ CD25+ T-cells (Treg cells) of the same individual to
the culture [66]. Among others, Orban et al. have carried out
a human study based on Treg induction by insulin 𝛽-chain
immunotherapy with no obvious benefit [67].
Hugues et al. could prevent NOD mice from developing
diabetes by a single low dose of streptozotocin provided
that 𝛽-cell apoptosis occurred but not in the RIP-CrmA
transgenic NOD mice in which 𝛽 cells expressed the caspase
inhibitor CrmA [68]. Rayat et al. achieved similar preven-
tion by intraperitoneal injection of in vitro streptozotocin-
treated islet cells into prediabetic female NOD mice [69].
According to Hauben’s review, autoimmunity is not under
all circumstances a pathologic process and provided that
the activation of Treg cells might keep the process limited
and the nature of the early immune response adequate;
it may participate in the elimination of damaged tissues
[5]. In BDC2.5 RAG-1-(recombination activating gene-1-)
deficient mice, the generation of both B- and T-lymphocytes
is impaired, and, in addition, they develop severe T1DM.
The development of diabetes in the mouse model could be
abrogated by the transfer of splenocytes on the 10th day of
life from NOD mice, irrespective of whether the CD25 (IL-2
receptor 𝛼-chain) has or has not been present on the cell
population [70]. Surprisingly, Balb/c mice expressing IFN-𝛾
in their 𝛽-cells turned out to be resistant to streptozotocin-
induced diabetes, while the controversial role of IL-10 (in
conjunction with NODMHChomozygosity) in autoimmune
diabetes development has been suggested in experiments
with transgenic mice expressing pancreatic IL-10 [71]. These
data suggest that limited autoimmunity is likely to have a role
in active tolerance [5], and the successful preventive attempts
by supporting insulitis lead us to considering the sequence of
other, for example, environmental factors.
4. Factors Influencing the Development of
Immune Response
The existence of synergic immunological stimuli affecting
separate pathways has been known for decades. However,
their relevance in autoimmune diabetes is the product of
recent investigation. In case of vaccination, it has been
known that one-peptide antigen by itself is not always suffi-
cient for triggering immune response. Furthermore, it is
likely to induce tolerance. In general, the antigens, which
are bigger and easily form aggregates, are more likely to
induce immune response, while smaller soluble antigens
primarily induce tolerance [72, 73]. Dresser proved in the
1960s that immunizationwith highly purified antigens induce
immunity only in a case when an adjuvant is provided [74].
Dresser used aspecific bacterial adjuvant, but similar results
could be achieved with endotoxin [75]. These observations
led to the classical theory that two concurrent triggers
are necessary for the appropriate induction of an immune
response [73]. This basic theory by Bretscher and Cohen
for B-lymphocytes [76] was later also proven in T-cell-
mediated responses [77, 78]. As later clarified, during antigen
presentation the APC provides numerous contact costimuli
(e.g., the APC surface B7 complex binding to the surface
CD28 of the T-cell) besides the MHC-II bound antigen
which—together with cytokines—are necessary for T-cell
activation. Janeway postulated that antigen presentation is
the decision making step of the immune response, and the
outcome (immunization or tolerance induction) depends
on whether the APC could bind any pathogen-associated
molecular pattern (PAMP) by its specific receptors (stranger
hypothesis). In Janeway’s theory, infections were the evo-
lutionary drive for the immune system which was justified
by the discovery of the TLRs by which the APCs detect
highly conserved nonhuman (primarily bacterial and fungal)
patterns. However, this theory seemed to be insufficient for
the interpretation of the immune response to tumors, grafts,
most viruses, and autoimmunity [73, 79]. Some of these
exceptions become questionable as some viral components
are ligands of intracellular TLRs through which they induce
the secretion of antiviral interferons (IFN-𝛼 and 𝛽): double-
stranded RNA of rota viruses is the ligand of TLR3, the
single-stranded RNA of the coxsackie-B virus, probably the
most often associated to T1DM, is the ligand of TLR7, while
cytomegalovirus (CMV) can be sensed by the recognition
of CpG DNA motif by TLR9 [80]. TLR4 functions as the
receptor of bacterial lipopolysaccharide (LPS), while TLR2
recognizes cell wall components mainly from gram positive
bacteria, mycobacteria, and yeast [81]. TLR2 and TLR4 are
located on the cell surface but they are also involved in sens-
ing some viruses. They primarily activate the nuclear factor
kappa B (NF-𝜅B) pathway and partly alternative pathways,
which results in the secretion of inflammatory cytokines
[80]. 𝛽-cell apoptosis might participate in the priming of
diabetogenic T-cells via a TLR2-dependent APC stimulation
[57].
Thedanger hypothesis byMatzinger states that the critical
signals for APCs besides the antigen are cell components
released from damaged cells (danger-associated molecular
patterns—DAMP) [73]. Shi et al. found that subcutaneous
injection of syngenic necrotic or apoptotic cells exerts sig-
nificant adjuvant effect on cytotoxic T-cell responses to oval-
bumine, while the cells alone were not immunogenic [82].
Some authors describe that particles of apoptotic cells can
be engulfed by macrophages and DCs, and after degradation
some components are presented both onMHC-I andMHC-II
complexes, hence their ability to trigger cytotoxic response
[83, 84]. The properties of the antigen presentation are
determined by the circumstances of the antigen-uptake: if it
occurs in a “peaceful” environment, the presentation will be
tolerogenic such as when apoptotic remnants are eliminated.
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If the appropriate factors potentiate the maturation of the
DCs, it will result in T-cell activation [85].
Heat shock proteins (HSPs) are highly conserved immu-
nogenic proteins that are involved in the pathogenesis of
a variety of immune-mediated disorders, including autoim-
mune diseases. HSPs might serve as autoantigens, and
antibodies against two epitope regions on HSP60 (AA394–
413 and AA435–454) were detected in high titres in sera
of children with T1DM [86]. Recently autoantibody against
HSP 10 was found in sera from the majority of patients
with fulminant type 1 diabetes (FT1DM) and also with
autoimmune pancreatitis (AIP), and authors even suggested
that an autoantibody against HSP 10 is a new diagnostic
marker for both AIP and FT1DM [87]. The lymphocyte
proliferative response to Mycobacterium leprae HSP65 of
NOD mice was higher compared to their counterparts from
I-Ed
𝛼
transgenic mice that show no insulitis. In addition,
splenocytes from NOD mice were able to transfer insulitis
to the previously resistant transgenic strain [88]. Many
cytoplasmatic components are suspected to exert adjuvant
effect as DAMPs, including HSPs [73], for example, HSP70,
HSP90, and HSP100 [89], which are able to stimulate the
maturation of DCs [90, 91]. Certain HSPs (e.g., HSP60 and
70) generate a signal via the LPS receptor (TLR4-CD14
complex) [92], and other authors suggested that LPS-free
HSP preparates were ineffective [93]. HSPs, also as carriers
of peptides, are taken up by APCs and the peptide they
carried can be presented onMHC-I [94]. Although a specific
HSP receptor is known (CD91) [95], the TLR2/4 cluster
is also involved in the uptake of HSP-peptide complexes
[94]. Miyagawa et al. even indicated the role of TLR4 in
binding the chemokine CXCL10, which is known to have an
important role in the development of insulitis [96]. Uric acid
is also able to promote the maturation of dendritic cells via
binding tomembrane lipids. After phagocytosis, it potentiates
inflammation through enhancing IL-1𝛽 secretion. Uric acid is
able to exert this effect only in such high concentration when
crystal forming appears [97].
5. Environmental Factors and Apoptosis
According to the DIPP (diabetes prediction and prevention)
study, autoantibody positivity is detectable by the age of 2
in the overwhelming majority of those who develop diabetes
until the age of 10 years [98].Therefore, the interplay between
genetic susceptibility and potential triggers is likely to play
a role at a very early age that gradually results in the
loss of balanced autotolerance in the upcoming years and
subsequently to the development of the clinical disease.
Seasonal accumulation of new cases led Adams in 1926 to
hypothesize the pathogenic role of viral infections. Rubella,
CMV, enteroviruses, mumps, and coxsackie virus are among
the most frequently suspected pathogens [99]. The potential
role of coxsackie-B virus was based on the serological results
of newly diagnosed T1DM patients in 1969 [100]. Later, the
viral RNA was detected from the sera of such patients [101].
It is not yet clear how these viruses might be able to exert
a diabetogenic effect. There is evidence that the rubella,
coxsackie, and mumps viruses are able to infect 𝛽-cells [24],
and there are experimental models for other viral infections
that might lead to fulminant diabetes [102]. The similarity
between human and viral proteins might offer an additional
explanation, and the coxsackie-B virus indeed does contain a
protein similar to the human glutamic acid decarboxylase-
65 (GAD65) [24]. Experimentally, it has been proven that
molecular mimicry is only able to trigger autoimmune
diabetes provided that there is a full identity between the
amino acid sequences as modeled in the RIP-gp (rat insulin
promoter) mice which expresses a glycoprotein (gp) of the
lymphocytic choriomeningitis virus (LCMV) in their 𝛽-cells
and after an infection rapidly develop diabetes [24, 103, 104].
On the other hand, an infection with a virus containing an
analogous but not identical epitope is able to promote the
ongoing autoimmunity [105]. The intensity of the ongoing
immune response might determine the effect of an infection
[24]. When older NOD mice—in which insulitis was already
present—were infected with certain coxsackie virus strains, it
resulted in the speed-up of the development of diabetes [106].
However, inoculating coxsackie-B virus (CBV) into young
NOD mice devoid of insulitis diminished the incidence of
diabetes until the fixed endpoint. Interestingly, themore pan-
creatovirulent the CBV strain was, the greater the protection
from T1DM onset was seen in coxsackie-B3-virus-induced
pancreatitis. The immunopathology of the protection in this
genetically susceptible mouse strain is not fully clarified.
Authors considered that virus induced pancreatitis reveals
specific host pancreatic antigens to the immune system that
suppress the autoimmune insulitis in the NOD mice [106].
Recently, acceleration of murin T1DM by rotavirus was also
described and associatedwith virus spread in regional lymph-
nodes and induction ofTh1-dependent antibody and cytokine
response [107].
Other environmental factors such as bovine insulin
containing homologous epitopes (molecular mimicry) might
also boost an ongoing autoimmune process. The suspected
environmental trigger bovine insulin differs only in three
amino acids from human insulin. Still, the titer of antibodies
against bovine insulin spontaneously decrease at the age of
12–18 months in those children in whom other diabetes-
associated autoantibodies were not detected, even though
they were carrying the HLA DQB1∗0302 haplotype. In
contrast, in those children who had at least two diabetes-
associated autoantibodies at this age, the spontaneous decline
in antibovine insulin antibody titer did not occur, instead the
titers further increased [108].
The early theory that described viruses and certain envi-
ronmental triggers as specific causes of T1DM via anti-
genic mimicry might only be sustained if taken into a
more complex view. Viral infections are able to mediate
the apoptotic process and some of the candidate genes
identified inGWAStudies are coding proteins that are actively
involved in a virus-host interplay that may—together in
combination—promote the autoimmune process.The 𝛽-cells
themselves possess pattern recognition receptors (such as
IFIH1—interferon induced with helicase C domain 1—, a
sensor of double-stranded viral RNA, a candidate gene
[10] and TLRs) which, via the activation of NF-𝜅B and
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Figure 1: In addition to proinflammatory cytokines such as IL-1 and IFN-𝛾, the signaling via IFIH1 and various other pathogen recognition
receptors mediate 𝛽-cell apoptotic death: upregulate certain BH3 proteins and also promote the secretion of numerous chemokines. Certain
BH3 “sensitizer” proteins, for example, DP5, bind to BCL2 and BCL-XL which inhibit BAX and BAK activation and at the same time liberate
the “activator” proteins (such as BIM and PUMA). PTPN2 is a negative regulator of the pancreatic 𝛽-cell apoptosis that reduces the BH3
protein-related apoptotic activation cascade in the 𝛽-cell.
STAT1, provide proapoptotic signals for the cell [109]. The
cytokines such as IFN-𝛾 and IL-1𝛽, which are known as
main mediators of 𝛽-cell apoptosis, exert their effect through
NF-𝜅B and STAT1 as well [109]. PTPN2 (protein tyrosine
phosphatase, non-receptor type 2), which is a candidate gene
according to GWAStudies has antiapoptotic activity at least
in part through the blockade of JNK1 (c-Jun N-terminal
protein kinase 1), which is responsible for the activation of
STAT1 and BCL2L11 (BCL2-like 11, BIM; described later).
Its inhibition on the translation level both in vitro (human
𝛽-cells) and in vivo supported IFN-induced 𝛽-cell apoptosis
[110]. NF-𝜅B and STAT1 signaling also upregulates MHC-I
expression on the cell surface, which might lead to a vicious
circle by making the 𝛽-cell more “visible” for cytotoxic
T-cells [24, 109]. Furthermore, in response to inflammatory
cytokines, 𝛽-cells are able to express MHC-II as well [111].
Recently, many interesting data have become known on
the process linking proapoptotic stimuli to the mitochon-
drial BAX (BCL2-associated X protein) and BAK (BCL2-
antagonist/killer) activation, which is the final common path
of cell death via apoptosis. In this intermediate phase, the
so-called BH3 (BCL2 homologous 3) proteins have a crucial
role. Based on their activity, they can be divided into two
groups: the sensitizers (e.g., DP5—death protein 5—) bind
to BCL2 (B-cell CLL/lymphoma 2) and BCL-XL (BCL2-
like protein 1), which inhibit BAX and BAK activation,
and at the same time liberate the activators (such as BIM
and PUM—p53 upregulated modulator of apoptosis—) from
this bond, which activate BAX and BAK [112] (Figure 1).
Gurzov and Eizirik describe that in triggering this process
endoplasmatic reticulum stress has an important role and in
vitro stressed 𝛽-cells showed higher DP5 expression [112].
With DP5 inhibition on the RNA level, the apoptotic rate
could be, diminished [109]. DP5 did not only have a positive
effect on cell survival, but DP5 gene knockout (GKO) mice
had larger 𝛽-cell mass and turned out to be resistant to high-
fat-diet-induced glucose intolerance, directly proving the link
between the immunological apoptotic and the metabolic
functions [113]. Among the activators, BIM seems to be
dominant. The higher apoptotic rate after PTPN2 inhibition
could be significantly diminished by BIM inhibition [110]. By
the inhibition of PUMA, mitochondrial BAX translocation
and both apoptosis could also be diminished [114]. The
combination of TNF-𝛼 IFN-𝛾 inducedDP5, PUMA, and BIM
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expression in human islets [115]. The figure summarizes the
signaling in the 𝛽-cell.
The apoptotic cell remnants that might be further
degraded by secondary necrosis as sources of endogenous
adjuvants and inflammatory mediators might enhance the
local immune response in a nonspecific manner (bystander
activation) and are also able to make other previously hidden
antigens available (antigenic spreading) [24]. From this view,
a viral infection might be able to flare the autoimmunity
up or, in the case of insufficient peripheral tolerance, even
initiate an autoimmune process. The 𝛽-cells are not only
targets but also active participants of the inflammation.
Eizirik et al. analyzed the transcriptome of human 𝛽-cells and
found that IFN-𝛾 and IL-1𝛽 exposure resulted in several fold
elevation of the chemokines CXCL-9, -10, -11, and CCL-2, -3,
-5 secreted by the 𝛽-cell [116]. The sera of T1DM patients
were shown to contain higher levels of CXCL10 compared
to healthy individuals and type 2 diabetic patients [117].
The expression of CXCR3, the receptor of CXCL-9, -10, and
-11 chemokines is typical of Th1 cells. Some groups were
able to effectively block the manifestation of diabetes in
prone mice by blocking CXCR3-linked signaling [118, 119].
However, they used the previously mentioned RIP-gpmouse,
which is a perfect model of antigenic mimicry but not of the
multifactorial human disease. Yamada et al. used a CXCR3
knockout NODmouse model and expected it to be protected
against diabetes. Surprisingly, the CXCR3−/− NOD mouse
developed diabetes even earlier, which turned out to be due
to impaired navigation of Treg cells to the islets [117].
6. Epigenetics
Although over the past fifty years there has been a (geo-
epidemiologically) significant increase in incidence of T1DM,
this is not in parallel with the frequency of the genetic risk.
Moreover, the prevalence of the MHC-II genes responsible
for approximately 40% of susceptibility has been decreased
[120]. Several environmental factors may contribute to com-
plex T1DM pathways and thus to disease manifestation.
Epigenetic regulation, as a missing link, has been proposed
not only to reflect the influence of environmental exposures,
gender, and aging, but also to explain the discordance in
monozygotic twins for the development of autoimmunity as
well.
Epigenetics is a mechanism defined by mainly heritable
changes of gene expression without altering directly the
DNA sequence, and thus it affects genotypes to be ulti-
mately manifested in diverse phenotypes. In general, the
epigenome can be modified at three main checkpoints, like
DNA methylation, posttranslational histone modifications,
and expression of noncoding RNAs, such asmiRNAs (micro-
RNAs) and lncRNAs (long noncoding RNAs). Epigenetics
plays a crucial role in the development and function of
different tissues and cells, including the immune system and
𝛽-cell mass expansion under stress in the pancreas [121, 122].
Maturation and differentiation of immune cells, and cytokine
gene expressions seem to be especially affected [123, 124].
Current lines of evidences suggest the multiple involvement
of epigenetics in the pathomechanism of T1DM: epigenetic
changes may influence disease outcome by affecting 𝛽-cell
homeostasis, insulin and glucose metabolism, the gut micro-
biome, and immune responses.
After detecting a significant increase in 𝛽-cell-derived
demethylated DNA in the Ins (insulin gene) yet before
the onset of hyperglycemia in (prediabetic) NOD mice,
Akirav et al. subsequently were able to confirm the increased
demethylation of CpG sites within the insulin gene in
primary human 𝛽-cells and also found increased levels of
demethylated insulinDNA in circulating𝛽-cell-derivedDNA
in patients with new-onset type 1 diabetes.They proposed this
observation as an alteration contributing to T1DMpathology,
as well as a potentially noninvasive approach for detecting in
vivo 𝛽-cell death [125].
By using the chromatin immunoprecipitation linked to
microarray (ChIP-chip) approach to compare genome wide
histone H3 lysine 9 dimethylation (H3K9me2) patterns in
peripheral blood lymphocytes and monocytes from T1DM
patients, the T1DM candidate gene CTLA4 has been dis-
played higher H3K9me2 at the promoter region yet standing
as an example of interface between genetic and epigenetic
information in T1DM [126].
Miao et al. observed marked variations in H3K9-
acetylation (H3K9Ac)—that is associatedwith promoters and
active genes—levels at the upstream regions of HLA-DRB1
and HLA-DQB1 in T1DMmonocytes and also demonstrated
increased expression of HLA-DRB1 and HLA-DQB1 on
monocytes in response to interferon and TNF treatment
that were accompanied by changes in H3K9Ac at the same
promoter regions as those seen in the patients’ cells. There-
fore, they suggest that the H3K9Ac status may regulate the
transcriptional response of HLA-DRB1 and HLA-DQB1 to
cytokine stimuli [127].
The complexity of epigenetic mechanisms is well char-
acterized by the recent finding that the promoter of the
Ins (insulin) gene is part of an extended “open” chromatin
domain and as such is in physical contact with the Syt8, a gene
that is located at 300 kb distance in the genome, and inter-
estingly this contact between Ins and Syt8 is strengthened by
glucose in pancreatic islets [128].
Certain miRNAs are also related to T1DM: miR-21a and
miR-93 were shown to be downregulated in peripheral blood
mononuclear cells of T1DM patients. Moreover, a population
of Treg cells of T1DM patients showed a higher expression
of miR-146 that is crucial in maintaining the suppressor
function of Treg cells, while a lower expression of eight other
miRNAs (20b, 31, 99a, 100, 125b, 151, 335, and 365) were found
[129, 130].
Furthermore, a role for long noncoding (lnc) RNAs, both
in the cis and trans regulation of transcription via interaction
with chromatin modifying complexes to target epigenetic
marks to particular genomic loci, has only been recently
described. An islet-specific lncRNA expressed from the Pdx1
locus regulates Pdx1 activity, a master gene of 𝛽-cell differ-
entiation and regulation, therefore has a potential impact
on maintaining glucose homeostasis. Long noncoding RNA
molecular studies might open a yet largely unrevealed novel
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layer of transcribed but not translated genetic information
and new dimensions in diabetes research [131–134].
7. Summary
Type 1 diabetes mellitus is a prototype disorder of both
endocrine and organ-specific autoimmune diseases. There is
a growing amount of evidence suggesting that autoimmunity
cannot be interpreted as a binary state. It rather becomes
pathologic through impaired regulation. From the view
of the congenital susceptibility, the role of environmental
factors might be revised as some might be considered rather
enhancers than triggers. The early and adequate nature
of the response with optimal limitation of autoimmunity
might be the difference between the physiologic and the
pathologic conditions [5].The impaired elimination of apop-
totic remnants may create a less tolerogenic inflammatory
environment favorable for the initiation of autoimmunity
[53]. The transient local inflammation due to, for example,
a viral infection in combination with the impaired immune
regulatory functions that are in part determined by the
genetic background may eventually lead to the generation
and expansion of autoreactive T-cells [24, 135]. Data from the
World Health Organization Diabetes Mondiale (WHO Dia-
mond) Project suggested the role of late enhancers: as the later
the disease onset was, the more the pronounced seasonality
evaluators could find [136]. Therefore, the possibility of an
early immunization as a preventive approachmight be raised.
GWAStudies made real breakthrough in identifying non-
HLA genetic variations that participate in the establishment
of the genetic susceptibility. In addition, the identification of
a number of candidate genes and their risk polymorphisms
GWAS contributed significantly to the understanding of
the molecular pathology of certain immune mechanisms.
Epigenetics has also been reported to contribute significantly
to the pathology of this autoimmune disease.
Themost recent national and international epidemiologic
data still show elevation in T1DM incidence in all age groups
but especially among the youngest, under 4 years [137, 138].
Although the role of certain viral infections cannot be
excluded in the priming, such epidemics have become even
less frequent, which is the theoretical basis of the hygiene
hypothesis. Yet, a germ-free environment might not only
exclude an immunomodulatory effect of various infections
[139], but also, if the time of the first infections is delayed, it
may more easily enhance latent autoimmunity. Interactions
of metabolic and immunologic processes are also likely to be
considered as between potential cause of the epidemiological
tendencies. According to the results of the search for diabetes
in the youth (USA), 35.4% of those diagnosed with diabetes
under the age of 20 are insulin resistant, and 19.5% also have
autoantibodies [140].
A number of clinical trials have been conducted or are
still under clinical investigation, and the framework of this
review limited us to comprehensively report all trials. Effector
and regulatory T-cells are known to differ in their affinity
to IL-2 and therefore theoretically provide a narrow range
where Treg induction by IL-2 is feasible without the induction
of effector T-cells (as summarized earlier) [41]. Induction of
immune tolerance via nasal, or oral whole insulin antigen,
intramuscular insulin B-chain and subcutaneous GAD65
(with alum) administration or subcutaneous hsp60
437–460
(p277) administration either failed to demonstrate clinically
significant improvement or resulted in controversial out-
comes [141]. Studies administering D-vitamin based on its
immunomodulatory properties have also failed to demon-
strate clear clinical benefit [142, 143]; nevertheless, a recent
study found that T1DM risk was highest among individuals
whose 25(OH)D vitamin levels were in the lowest 20% of
those measured and concluded that low 25(OH)D-vitamin
levels may predispose young adults to the development of
T1DM [144].
Our study group have reported earlier that the dipeptidyl-
peptidase-4 (DPP-4)-incretin axis might be dysregulated and
the serumDPP-4 enzymatic activity is higher in patients with
T1DM than in healthy controls [145]. Blandino-Rosano et al.
found that in vitro GLP-1 (glucagon-like peptide-1) is able
to reverse the inhibition of extracellular signal-regulated
kinase 1 and 2 (ERK1 and 2) phosphorylation and the 𝛽-cell
antiproliferative effect of proinflammatory cytokines IL-1𝛽,
IFN-𝛾, and TNF-𝛼 [2]. In addition to the 𝛽-cell protective
effect of GLP-1, the incretin agonists might have a role in
the maintenance of the peripheral Treg cell population [146].
The results of a few pilot studies indicated a lower amount
of insulin needed to gain similar (or even better) glycemic
control using a DPP-4 inhibitor or a GLP-1 agonist in combi-
nationwith the insulin therapy and also significantly less time
spent in hypoglycemia when the GLP-1 agonist Liraglutide
therapy was applied with insulin in T1DM patients with
residual 𝛽-cell function [147, 148]. Therefore, lowering the
time spent with the glucose levels below 3.9mmol/L might
be an advantage in the everyday clinical praxis because
hypoglycaemia is still an existing problem.
Either the early immunization against the potential
enhancers in a susceptible population thatmight be a realistic
approach in prevention programs or the immune tolerance
induction in combination with parallel therapies targeting
𝛽-cell recovery that might provide future alternatives for
the therapy of the already developed disease will enter a
highly competitive field where the already existing standard
care provides T1DM patients with good quality of life and
acceptable life expectancy [149].
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